Amneal Receives FDA Approval for Parkinson’s Treatment - The capsules are expected to be available to US patients in September 2024.

[Farooqji]

CREXONT shown a statistically significant improvement in “good on” time for PD patients.

Amneal Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its CREXONT extended-release capsules for Parkinson’s disease (PD) treatment. The oral carbidopa (CD)/levodopa (LD) formulation that makes up CREXONT aims to provide patients with a more consistent “good on” time, which relates to a period of time a patient is free of dyskinesia (involuntary movements and muscle spasms).

pharmaceuticalmanufacturer....

[nednedned]

You already posred this